This trial is designed to evaluate olanzapine compared to the metoclopramide in the treatment of break through emesis after prophylaxis with dexamethasone, 5-HT 3 receptor antagonists and aprepitant in patients receiving chemotherapy. Efficacy will be assessed using a modified MASCC questionaire with a visual analog scale.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Enrollment
23
1x10mg per day for three days
3x10mg per day for three days
Martin-Luther-University Halle-Wittenberg, Department for Oncology and Hematology, Ernst-Grube-Strasse 40
Halle, Saxony-Anhalt, Germany
Clinical benefit rate
no vomitus, no further rescue medication, nausea \< 25mm on the visual analog scale (VAS) or reduction on the VAS of \>50%
Time frame: three days
safety
according to NCI-CTC-AE version4.0
Time frame: five days
Quality of life
using EORTC-QLQ-C30
Time frame: 5 days
change in urinary excretion of 5 hydroxy indole acetic acid
measurement in 24 hours urine samples
Time frame: 5 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.